JFL Life Sciences Key Ratios
NSE: JFLLIFE
₹10.75
₹0.00 (0.00%)As on 28-Aug-2026 09:55IST
Market cap
₹35 Cr
Revenue (TTM)
₹131 Cr
P/E Ratio
5.2
P/B Ratio
0.8
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -82.39 | -4.17 | 55.69 | 45.30 | 32.01 |
| EBIT | -45.27 | 6.29 | 77.82 | 44.82 | 41.33 |
| Net Profit | -32.95 | 49.20 | 124.11 | 31.58 | 63.85 |
| EPS | -32.96 | 49.18 | 14.34 | 31.58 | 47.31 |
| Book Value | -- | -- | 16.26 | 12.44 | 31.42 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 8.59 | 9.76 | 8.21 | 8.10 | 8.78 |
| Net Margin
| 5.65 | 6.28 | 5.17 | 4.87 | 5.07 |
| Return on equity
| 11.94 | 15.93 | 15.37 | 15.00 | 11.08 |
| Return on Capital
| 15.18 | 16.82 | -- | 18.20 | 15.81 |
| Return on Assets
| 6.63 | 6.59 | 7.60 | 7.19 | 6.47 |
| Debt to Equity (x)
| -- | -- | 0.15 | 0.47 | 0.27 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
--
|
18.20
|
15.81
|
11.53
|
15.45
|
|
Peer Median
|
--
|
19.34
|
21.76
|
21.89
|
--
|
ROE
15.37
Higher than Peers by 0.02
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
15.37
|
15.00
|
11.08
|
9.73
|
12.90
|
|
Peer Median
|
15.35
|
16.97
|
17.93
|
16.42
|
--
|
ROA
7.60
Lower than Peers by 2.75
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
7.60
|
7.19
|
6.47
|
6.25
|
5.77
|
|
Peer Median
|
10.35
|
9.88
|
12.81
|
12.32
|
--
|
EBIT Margin
8.21
Lower than Peers by 9.80
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
8.21
|
8.10
|
8.78
|
8.89
|
8.18
|
|
Peer Median
|
18.01
|
18.96
|
18.93
|
21.05
|
--
|
Net Margin
5.17
Lower than Peers by 9.29
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
5.17
|
4.87
|
5.07
|
7.01
|
6.32
|
|
Peer Median
|
14.45
|
13.29
|
14.94
|
15.51
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
--
|
5.69
|
6.28
|
8.04
|
7.55
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
55.69
Higher than Peers by 43.74
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
55.69
|
60.14
|
76.25
|
8.68
|
27.50
|
|
Peer Median
|
11.95
|
12.97
|
10.90
|
13.44
|
--
|
EBIT Growth
77.82
Higher than Peers by 56.22
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
77.82
|
47.59
|
74.11
|
18.19
|
-29.82
|
|
Peer Median
|
21.60
|
15.05
|
15.01
|
23.50
|
--
|
Net Profit Growth
124.11
Higher than Peers by 101.38
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
124.11
|
53.96
|
25.98
|
17.47
|
-0.01
|
|
Peer Median
|
22.73
|
11.89
|
14.80
|
30.12
|
--
|
EPS Growth
14.34
Lower than Peers by 5.69
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
14.34
|
53.96
|
25.97
|
17.48
|
-27.09
|
|
Peer Median
|
20.03
|
12.16
|
14.27
|
29.02
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
--
|
16.26
|
10.91
|
10.25
|
185.81
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.15
Higher than Peers by 0.15
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
0.15
|
0.47
|
0.27
|
0.16
|
0.22
|
|
Peer Median
|
0.00
|
0.05
|
0.06
|
0.03
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
--
|
0.30
|
0.25
|
0.13
|
0.18
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.73
Lower than Peers by 0.36
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
1.73
|
1.73
|
1.88
|
2.11
|
2.72
|
|
Peer Median
|
2.08
|
1.93
|
1.90
|
2.23
|
--
|
Quick Ratio
1.07
Lower than Peers by 0.46
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
1.07
|
1.07
|
1.15
|
1.35
|
1.88
|
|
Peer Median
|
1.54
|
1.52
|
1.46
|
1.59
|
--
|
Interest Coverage
5.01
Lower than Peers by 14.37
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
5.01
|
5.08
|
6.67
|
5.41
|
3.61
|
|
Peer Median
|
19.38
|
19.95
|
24.96
|
45.29
|
--
|
Operating Efficiency
Debtors to sales
40.69
Higher than Peers by 19.31
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
40.69
|
40.54
|
42.59
|
55.53
|
52.48
|
|
Peer Median
|
21.38
|
19.87
|
21.77
|
20.10
|
--
|
Asset Turnover
1.47
Higher than Peers by 0.75
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
1.47
|
1.47
|
1.28
|
0.88
|
0.88
|
|
Peer Median
|
0.72
|
0.77
|
0.76
|
0.81
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
--
|
122.52
|
135.23
|
189.47
|
180.15
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
--
|
80.27
|
86.92
|
111.97
|
117.97
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
--
|
74.66
|
83.56
|
90.91
|
116.67
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
--
|
128.13
|
138.58
|
210.52
|
181.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
5.24
Lower than Peers by 28.74
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
5.24
|
4.41
|
13.85
|
4.37
|
4.31
|
|
Peer Median
|
33.99
|
34.30
|
26.81
|
39.85
|
--
|
Price / Book Value
0.76
Lower than Peers by 4.31
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
0.76
|
0.62
|
1.46
|
1.22
|
1.12
|
|
Peer Median
|
5.06
|
5.19
|
4.65
|
6.11
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
--
|
--
|
--
|
0.64
|
--
|
|
Peer Median
|
0.49
|
0.50
|
0.61
|
0.37
|
--
|
EV/EBITDA
4.66
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
4.66
|
4.12
|
8.30
|
9.52
|
7.80
|
|
Peer Median
|
--
|
30.46
|
27.02
|
34.57
|
--
|
Market Cap
35
Lower than Peers by 19,090
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
JFL Life Sciences
|
35
|
28
|
58
|
43
|
36
|
|
Peer Median
|
19,125
|
18,009
|
20,914
|
25,297
|
--
|